title: Glucose metabolism in RIF-1 tumors after reduction in blood flow: an in vivo 13C and 31P NMR study.
abstract: Low pH appears to enhance the effectiveness of therapeutic hyperthermia. 13C and 31P NMR spectroscopy have been employed to examine the possibility that elevating glucose in a solid tumor while simultaneously reducing tumor blood flow would induce a more profound acidosis than either treatment alone. When blood flow in RIF-1 tumors was acutely reduced by administration of hydralazine and additional glucose was delivered locally by intratumoral injection, tumor acidosis (as determined by 31P NMR spectroscopy) during the period of reduced blood flow was not enhanced, relative to administration of hydralazine alone. Tumor NTP/P1 ratios decreased significantly within 20 min of hydralazine administration, whether or not glucose was injected, although NTP/P1 ratios were slightly higher in tumors that received extra glucose. Tumor lactate concentrations were not significantly different in glucose-supplemented tumors, despite glucose concentrations that were 4 to 5 times higher. When the added glucose was labeled with 13C, no correlation was detected between the pH in an individual tumor and the intensity of the 3-[13C]-lactate resonance in the same tumor.
authors.affiliation: Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21025-2195.
authors.forename: Z M
authors.initials: ZM
authors.lastname: Bhujwalla
authors.forename: D C
authors.initials: DC
authors.lastname: Shungu
authors.forename: J C
authors.initials: JC
authors.lastname: Chatham
authors.forename: J P
authors.initials: JP
authors.lastname: Wehrle
authors.forename: J D
authors.initials: JD
authors.lastname: Glickson
mesh_terms: D000138:Acidosis / Q000378:metabolism; D000409:Alanine / Q000378:metabolism; D000818:Animals; D001345:Autoradiography; D001786:Blood Glucose / Q000032:analysis; D002247:Carbon Isotopes; D004734:Energy Metabolism; D005260:Female; D005947:Glucose / Q000008:administration & dosage / Q000378:metabolism* / Q000493:pharmacokinetics; D006830:Hydralazine / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D015552:Injections, Intralesional; D007773:Lactates / Q000097:blood / Q000378:metabolism; D019344:Lactic Acid; D009682:Magnetic Resonance Spectroscopy; D051379:Mice; D008809:Mice, Inbred C3H; D008815:Mice, Inbred Strains; D010759:Phosphorus Isotopes; D012039:Regional Blood Flow / Q000187:drug effects; D012513:Sarcoma, Experimental / Q000098:blood supply* / Q000378:metabolism*
chemical_list: D001786:Blood Glucose; D002247:Carbon Isotopes; D007773:Lactates; D010759:Phosphorus Isotopes; D006830:Hydralazine; D019344:Lactic Acid; D005947:Glucose; D000409:Alanine